display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
Immune checkpoint association
nivolumab plus ipilimumab STIMULI

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons